Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Eur J Gastroenterol Hepatol. 2014 Oct;26(10):1073–1082. doi: 10.1097/MEG.0000000000000152

Table 3. Drug interaction potential of the most utilized medications in U.S. patients with HCV by total number of prescriptions filled.

Medication Number of claims Boceprevir* Telaprevir*
None Interaction CI NL None Interaction CI NL
1. Acetaminophen/hydrocodone bitartrate 367,166 X§ X§
2. Ribavirin 176,842 X X
3. Zolpidem tartrate 169,811 X X
4. Levothyroxine sodium 155,926 X X
5. Alprazolam 146,362 X X
6. Lisinopril 123,616 X X
7. Peginterferon alfa-2a 120,191 X X
8. Oxycodone 118,753 X X
9. Furosemide 100,413 X X
10. Amlodipine besylate 93,776 X X
11. Omeprazole 87,895 X X
12. Acetaminophen/oxycodone 81,332 X§ X§
13. Esomeprazole magnesium 80,526 X§ X
14. Metformin HCl 78,229 X X
15. Escitalopram oxalate 74,171 X X
16. Spironolactone 72,277 X X
17. Hydrochlorothiazide 71,311 X X
18. Bupropion HCl 66,680 X X
19. Tramadol HCl 65,803 X X
20. Pantoprazole sodium 62,622 X X
21. Metoprolol succinate 61,663 X X
22. Lorazepam 59,950 X X
23. Azithromycin 59,784 X X
24. Atenolol 59,054 X X
25. Peginterferon alfa-2b 58,846 X X
26. Sertraline 58,004 X X
27. Clonazepam 57,336 X X
28. Citalopram hydrobromide 55,375 X X
29. Gabapentin 53,583 X X
30. Trazodone 53,564 X X
31. Prednisone 53,292 X X
32. Tacrolimus 50,389 X X
33. Amoxicillin 49,285 X X
34. Cyclobenzaprine 48,168 X X
35. Diazepam 48,097 X X
36. Potassium chloride 47,627 X X
37. Sulfamethoxazole/trimethoprim 46,555 X§ X§
38. Venlafaxine 46,376 X X
39. Metoprolol tartrate 45,848 X X
40. Carisoprodol 45,149 X X

Abbreviations: HCV, Hepatitis C Virus; CI, Contraindicated; NL, Not listed

*

Interaction potential based on Liverpool Drug Interaction charts[21] with None: “No clinically significant interaction expected”; Interaction: “Potential interaction – may require close monitoring, alteration of drug dosage or timing of administration; Contraindicated: “These drugs should not be coadministered”

Chart indicates drug-disease interaction only with hepatic insufficiency/cirrhosis and/or pharmacokinetic interaction unlikely

§

Interaction has not been assessed and has been predicted based on metabolic profiles of the drugs